| Market Capitalization (Millions $) |
2,285 |
| Shares
Outstanding (Millions) |
59 |
| Employees |
246 |
| Revenues (TTM) (Millions $) |
825 |
| Net Income (TTM) (Millions $) |
186 |
| Cash Flow (TTM) (Millions $) |
260 |
| Capital Exp. (TTM) (Millions $) |
34 |
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc is a clinical-stage biopharmaceutical company that was founded in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. The company is focused on developing and commercializing innovative therapies for patients with sleep and central nervous system disorders.
Harmony Biosciences Holdings Inc is primarily known for its lead product, WAKIXe (pitolisant), which was approved by the U.S. Food and Drug Administration (FDA) in 2019 for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy. Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations.
WAKIX represents a breakthrough in the treatment of narcolepsy as it works differently from existing treatments. It is a first-in-class medication that selectively targets the histamine 3 (H3) receptor, which is involved in the regulation of wakefulness and sleep. By activating this receptor, WAKIX increases histamine release in the brain, which helps to promote wakefulness.
Apart from WAKIX, Harmony Biosciences has a pipeline of other innovative compounds at various stages of development for central nervous system disorders. These include pitolisant, which is being evaluated for the treatment of patients with obstructive sleep apnea; and pitolisant-sodium oxybate, a combination therapy being developed for the treatment of narcolepsy.
Harmony Biosciences is also dedicated to bringing innovation and transformation to the field of sleep and central nervous system disorders. The company has a robust research and development program that is focused on identifying new molecular targets and developing new therapies to address unmet medical needs in the field.
In addition to developing innovative therapies, Harmony Biosciences is committed to improving the lives of patients with sleep and central nervous system disorders. The company collaborates with patient advocacy groups, healthcare professionals, and academic institutions to support research, education, and awareness of these disorders.
Company Address: 630 W. Plymouth Meeting 19462 PA
Company Phone Number: 539-9800 Stock Exchange / Ticker: NASDAQ HRMY
|
1.52% 
100.27 %